The	O
EGFR	O
-	O
GEP100	O
-	O
Arf6	O
-	O
AMAP1	O
signaling	O
pathway	O
specific	O
to	O
breast	B-Cancer
cancer	I-Cancer
invasion	O
and	O
metastasis	O
.	O

Tumors	B-Cancer
are	O
tissue	B-Tissue
-	O
specific	O
diseases	O
,	O
and	O
their	O
mechanisms	O
of	O
invasion	O
and	O
metastasis	O
are	O
highly	O
diverse	O
.	O

In	O
breast	B-Cancer
cancer	I-Cancer
,	O
biomarkers	O
that	O
specifically	O
correlate	O
with	O
the	O
invasive	O
phenotypes	O
have	O
not	O
been	O
clearly	O
identified	O
.	O

A	O
small	O
GTPase	O
Arf6	O
primarily	O
regulates	O
recycling	O
of	O
plasma	B-Cellular_component
membrane	I-Cellular_component
components	I-Cellular_component
.	O

We	O
have	O
shown	O
that	O
Arf6	O
and	O
its	O
effector	O
AMAP1	O
(	O
DDEF1	O
,	O
DEF1	O
,	O
ASAP1	O
and	O
centaurin	O
beta4	O
)	O
are	O
abnormally	O
overexpressed	O
in	O
some	O
breast	B-Cancer
cancers	I-Cancer
and	O
used	O
for	O
their	O
invasion	O
and	O
metastasis	O
.	O

Overexpression	O
of	O
these	O
proteins	O
is	O
independent	O
of	O
the	O
transcriptional	O
upregulation	O
of	O
their	O
genes	O
,	O
and	O
occurs	O
only	O
in	O
highly	O
malignant	B-Cell
breast	I-Cell
cancer	I-Cell
cells	I-Cell
.	O

We	O
recently	O
identified	O
GEP100	O
(	O
BRAG2	O
)	O
to	O
be	O
responsible	O
for	O
the	O
Arf6	O
activation	O
to	O
induce	O
invasion	O
and	O
metastasis	O
,	O
by	O
directly	O
binding	O
to	O
ligand	O
-	O
activated	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
.	O

A	O
series	O
of	O
our	O
studies	O
revealed	O
that	O
for	O
activation	O
of	O
the	O
invasion	O
pathway	O
of	O
EGFR	O
,	O
it	O
is	O
prerequisite	O
that	O
Arf6	O
and	O
AMAP1	O
both	O
are	O
highly	O
overexpressed	O
,	O
and	O
that	O
EGFR	O
is	O
activated	O
by	O
ligands	O
.	O

Pathological	O
analyses	O
indicate	O
that	O
a	O
significant	O
large	O
population	O
of	O
human	O
ductal	B-Cancer
cancers	I-Cancer
may	O
utilize	O
the	O
EGFR	O
-	O
GEP100	O
-	O
Arf6	O
-	O
AMAP1	O
pathway	O
for	O
their	O
malignancy	O
.	O

Microenvironments	O
have	O
been	O
highly	O
implicated	O
in	O
the	O
malignancy	O
of	O
mammary	B-Cancer
tumors	I-Cancer
.	O

Our	O
results	O
reveal	O
an	O
aspect	O
of	O
the	O
precise	O
molecular	O
mechanisms	O
of	O
some	O
breast	B-Cancer
cancers	I-Cancer
,	O
in	O
which	O
full	O
invasiveness	O
is	O
not	O
acquired	O
just	O
by	O
intracellular	B-Immaterial_anatomical_entity
alterations	O
of	O
cancer	B-Cell
cells	I-Cell
,	O
but	O
extracellular	B-Immaterial_anatomical_entity
factors	O
from	O
microenvironments	O
may	O
also	O
be	O
necessary	O
.	O

Possible	O
translation	O
of	O
our	O
knowledge	O
to	O
cancer	B-Cancer
therapeutics	O
will	O
also	O
be	O
discussed	O
.	O

